Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Dec 05, 2019 11:27am
169 Views
Post# 30425122

RE:Address the shareholders

RE:Address the shareholders

I can empathize with your comments as I felt that way this time last year. Nothing was said then, and nothing will be said now. All I know is that shareholders should be very vocal come AGM if management recieves top bonuses again this year! 

I would argue that they recieve cash bonuses for the targets they did meet (european approval), but little to no options should be granted for the abismal sales and continually delayed timelines. Trograzo is growing slower than was communicated and Egrifta SV was finally "commercially lauched" with only days left in the fiscal year after many delays. 

Shareholders should be furious at the thought of their positions being diluted by management options at these low levels. If anything, the options should be granted at the 52 week highs because granting them at lows is simply rewarding the apathetic attitude that helped get us back to this <$4CAD level.




Bucknelly21 wrote: Though highly unlikely at this point there should be some sort of address to the shareholders because it's gotten far pay the point of insane in my opinion 

 

Bullboard Posts